Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project
Por:
Valero-Jaimes, JA, Lopez-Gonzalez, R, Martin-Martinez, MA, Garcia-Gomez, C, Sanchez-Alonso, F, Sanchez-Costa, JT, Gonzalez-Juanatey, C, Revuelta-Evrad, E, Diaz-Torne, C, Fernandez-Espartero, C, Perez-Garcia, C, Torrente-Segarra, V, Sanchez-Nievas, G, Perez-Sandoval, T, Font-Ugalde, P, Garcia-Vivar, ML, Aurrecoechea, E, Maiz-Alonso, O, Valls-Garcia, R, Miranda-Filloy, JA, Llorca, J, Castaneda, S, Gonzalez-Gay, MA, CARMA Study Grp
Publicada:
1 feb 2021
Resumen:
Objective: Since obesity has been associated with a higher inflammatory burden and worse response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to confirm the potential association between body mass index (BMI) and disease activity in a large series of patients with CIRDs included in the Spanish CARdiovascular in rheuMAtology (CARMA) registry. Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined when BMI (kg/m(2)) was >30 according to the WHO criteria. Scores used to evaluate disease activity were Disease Activity Score of 28 joints (DAS28) in RA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS, and modified DAS for PsA. Results: Data from 2234 patients (775 RA, 738 AS, and 721 PsA) were assessed. The mean +/- SD BMI at the baseline visit were: 26.9 +/- 4.8 in RA, 27.4 +/- 4.4 in AS, and 28.2 +/- 4.7 in PsA. A positive association between BMI and disease activity in patients with RA (beta = 0.029; 95%CI (0.01-0.05); p = 0.007) and PsA (beta = 0.036; 95%CI (0.015-0.058); p = 0.001) but not in those with AS (beta = 0.001; 95%CI (-0.03-0.03); p = 0.926) was found. Disease activity was associated with female sex and rheumatoid factor in RA and with Psoriasis Area Severity Index and enthesitis in PsA. Conclusions: BMI is associated with disease activity in RA and PsA, but not in AS. Given that obesity is a potentially modifiable factor, adequate control of body weight can improve the outcome of patients with CIRD and, therefore, weight control should be included in the management strategy of these patients.
Filiaciones:
Valero-Jaimes, JA:
Hosp Univ Donosti, Div Rheumatol, San Sebastian 20014, Spain
Lopez-Gonzalez, R:
Hosp Univ Hosp Gen Virgen de la Concha, Div Rheumatol, Zamora 49022, Spain
Martin-Martinez, MA:
Res Unit Spanish Soc Rheumatol, Madrid 28001, Spain
Garcia-Gomez, C:
Consorci Sanitari Terrassa, Div Rheumatol, Barcelona 08191, Spain
Sanchez-Alonso, F:
Res Unit Spanish Soc Rheumatol, Madrid 28001, Spain
Sanchez-Costa, JT:
Res Unit Spanish Soc Rheumatol, Madrid 28001, Spain
Gonzalez-Juanatey, C:
Hosp Univ Lucus Augusti, Div Cardiol, Lugo 27003, Spain
Revuelta-Evrad, E:
Hosp Gen Univ Ciudad Real, Div Rheumatol, Ciudad Real 13005, Spain
Diaz-Torne, C:
Hosp Santa Creu & Santa Pau, Div Rheumatol, Barcelona 08041, Spain
Fernandez-Espartero, C:
Hosp Univ Mostoles, Div Rheumatol, Madrid 28935, Spain
Perez-Garcia, C:
Hosp Mar, Div Rheumatol, Barcelona 08003, Spain
Torrente-Segarra, V:
Hosp Comarcal Alt Penedes Garraf, Div Rheumatol, Barcelona 08720, Spain
Sanchez-Nievas, G:
Complejo Hosp Univ Albacete, Div Rheumatol, Albacete 02006, Spain
Perez-Sandoval, T:
Complejo Asistencial Univ Leon, Div Rheumatol, Leon 24071, Spain
Font-Ugalde, P:
Hosp Univ Reina Sofia, Div Rheumatol, Cordoba 14004, Spain
Garcia-Vivar, ML:
Hosp Univ Basurto, Div Rheumatol, Bilbao 48013, Spain
Aurrecoechea, E:
Hosp Sierrallana, Div Rheumatol, Santander 39300, Spain
Maiz-Alonso, O:
Hosp Univ Donosti, Div Rheumatol, San Sebastian 20014, Spain
Valls-Garcia, R:
Hosp Univ Palamos, Div Rheumatol, Barcelona 17230, Spain
Miranda-Filloy, JA:
Hosp Univ Lucus Augusti, Div Rheumatol, Lugo 27003, Spain
Llorca, J:
Univ Cantabria, Santander 39005, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Santander 39005, Spain
Castaneda, S:
Univ Autonoma Madrid UAM, Hosp Univ Princesa, Div Rheumatol, IIS Princesa,EPID Future, Madrid 28006, Spain
Gonzalez-Gay, MA:
Univ Cantabria, Hosp Univ Marques de Valdecilla, Div Rheumatol, Santander 39008, Spain
IDIVAL, Div Rheumatol, Epidemiol Genet & Atherosclerosis Res Grp Syst In, Santander 39011, Spain
Univ Witwatersrand, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Fac Hlth Sci, ZA-2050 Johannesburg, South Africa
Green Published, gold
|